Zhi Tong Cai Jing·2025-11-27 11:41Core Viewpoint - Junshi Biosciences (01877) plans to invest temporarily idle raised funds in low-risk, high-liquidity principal-protected investment products, adhering to relevant regulations [1] Group 1: Investment Strategy - The company intends to use a maximum of RMB 2.4 billion (including principal) of temporarily idle raised funds for cash management [1] - Investment products include but are not limited to notice deposits, time deposits, agreement deposits, combination deposits, certificates of deposit, and structured deposits [1] - The investment will not be used for pledging or for securities investment purposes [1] Group 2: Investment Duration and Management - The company plans to invest the idle funds in tranches with varying maturities, with the longest maturity not exceeding 12 months [1] - Within the specified limit and duration, the funds can be used in a rolling manner [1]